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ERADAll newly synthesized proteins are subject to quality control check-points, which prevent aberrant polypeptides
from harming the cell. For proteins that ultimately reside in the cytoplasm, components that also reside in the
cytoplasm were known for many years to mediate quality control. Early biochemical and genetic data indicated
that misfolded proteins were selected by molecular chaperones and then targeted to the proteasome (in eukary-
otes) or to proteasome-like particles (in bacteria) for degradation. What was less clear was how secreted and
integral membrane proteins, which in eukaryotes enter the endoplasmic reticulum (ER), were subject to quality
control decisions. In this review, we highlight early studies that ultimately led to the discovery that secreted and
integral membrane proteins also utilize several components that constitute the cytoplasmic quality control
machinery. This component of the cellular quality control pathway is known as ER associated degradation, or
ERAD. This article is part of a Special Issue entitled: Functional and structural diversity of endoplasmic reticulum.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Every newly synthesized protein must transition from a nascent
polypeptide chain, which lacks signiﬁcant secondary structure, into its
folded and stable conformation. During this process even relatively
simple proteins are susceptible to inappropriate interactions with the
complex mixture of macromolecules inside the cell. In turn, larger and
more complex proteins usually possess multiple domains that need to
fold independently before the ﬁnal tertiary structure is attained, and
proteins in multi-subunit complexes must identify their partners. To
assist in this process the cell has evolved a diverse set ofmolecular chap-
erones. Molecular chaperones most commonly interact with exposed,
hydrophobic portions in soluble polypeptide chains, thus preventing
protein aggregation [1–4]. Some molecular chaperones may even pro-
vide an energetically favorable folding environment. Other members of
this protein family catalyze chemical reactions, such as disulﬁde bond
formation or proline isomerization, which directly facilitates protein
folding.
The endoplasmic reticulum (ER) is a major folding organelle in the
cell. All proteins destined to reside in membranes or to be secreted
pass through this organelle, leading to a high concentration of different
folding intermediates in various stages of completion [1,2]. The foldingonal and structural diversity of
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rights reserved.of integral membrane proteins is challenging, as hydrophobic domains
must be inserted into a lipid environment in their proper topological
orientation, while soluble portions of the protein must fold in solution.
Initial steps during the folding pathway take place co-translationally,
but in at least some cases the ﬁnal conformation can be attained only
once translation is complete [5]. As might be anticipated, for most
multi-spanning membrane proteins this process is quite inefﬁcient
and even wild type proteins under ideal conditions undergomany fold-
ing problems. Indeed, a growing body of evidence indicates that only a
fraction of the total population of somemembrane proteins reach mat-
uration and are stable (see for example [6–9]).
Because a signiﬁcant population of proteins misfold or become
damaged after synthesis—and because these aberrant species might
exhibit toxic effects on cellular health—all cells possess a quality control
system that identiﬁes and degrades polypeptides that fail to mature
[10,11]. The two major pathways for protein disposal in eukaryotes
are the lysosome and the cytoplasmic proteasome, and the existence
and importance of these pathways have long been appreciated. It is
also clear that other organelles, such as the mitochondria, the ER, and
the Golgi apparatus, harbor speciﬁc proteases. Because the ER and
Golgi represent compartments through which proteins travel en route
to the plasma membrane or to the extracellular space, the proteases in
these organelles are primarily devoted tomaturation events that gener-
ate active forms of proteins that pass through the secretory pathway,
but these proteases may not be suitable to mediate quality control.
As secreted and integral membrane proteins are synthesized, an
embedded hydrophobic signal sequence delivers the nascent chain–
ribosome complex to the ER membrane, an event that requires the
function of the signal recognition particle (SRP) and an ER associated
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import, or translocation, of the nascent protein into the ER membrane
(if the protein is an integral membrane protein) or into the ER lumen
(if the protein is soluble). Approximately one-third of all eukaryotic
proteins follow this path [14], which places a signiﬁcant burden on
the ER to ensure that these proteins fold efﬁciently. But, as noted
above, protein folding is inefﬁcient, and this event is magniﬁed when
one considers that secreted proteins may possess genetic mutations
and that cellular stresses, which are quite commonly encountered,
may overwhelm the ability of molecular chaperones to function efﬁ-
ciently. Consequently, for many years, it was assumed that a protein
quality control system existed within the ER that would identify and
degrade misfolded proteins. An efﬁcient ER quality control machine is
vital as the cargo that passes through this compartment includes essen-
tial plasma membrane receptors, secreted signaling molecules and
regulatory particles that control trafﬁcking and delivery to organelles
within the cell. In fact, the quality control machinery is so robust that
slowly folding, wild type proteins can be degraded [2,5,15]. From an
evolutionary perspective, it is better for the cell to remove a potentially
toxic protein than to risk the threat posed by these species in order to
save energy and increase the efﬁciency of protein production.
For many years, signiﬁcant efforts were directed toward identifying
the resident machinery and protease(s) that mediate protein quality
control in the ER. In this review, we highlight the conclusions obtained
from a select number of these important papers. In the end, however,
it was clear that proteins that failed to pass ER quality control were
not exclusively selected by ER resident factors, and that degradation
occurred—surprisingly—in the cytoplasm and was mediated by the
proteasome. This pathway was then referred to as ER associated degra-
dation (ERAD) [16]. Before we survey early work in this ﬁeld, we will
ﬁrst discuss general features underlying the selection and degradation
of ERAD substrates.
2. Basic features underlying ER associated degradation
The elimination of misfolded proteins from the ER is a complex
multi-step process that involves the coordination of many proteins
in both the ER and the cytoplasm [17–21]. To enter the ERAD pathway
a protein must ﬁrst be recognized. It must then be targeted for trans-
port across or from the ER membrane. As it is dislocated from the ER
membrane, the ERAD substrate interacts with a ubiquitin ligase and
becomes polyubiquitinated. The substrate is then delivered to the
cytoplasmic proteasome, de-ubiquitinated, and ﬁnally fed into the
proteasome for destruction.
The ﬁrst step during ER quality control is substrate recognition.
Recognition is most commonly mediated by molecular chaperones,
which interact with a hydrophobic region that should normally be
buried within the protein, is involved in an interaction with another
subunit of a multi-protein complex, or is embedded within the
lipid bilayer. Members of the Hsp70 chaperone family and Hsp40
co-chaperones are frequently employed for ERAD substrate selec-
tion, although Hsp90 and the lumenal protein disulﬁde isomerase
(PDI) also engage some ERAD substrates and seem to be involved in
quality control decisions (see for example [22–25]). It is still unclear if
Hsp90 binding can mediate degradation or if futile Hsp90 cycling
ultimately leads to Hsp70 directed ERAD. Depending on the topology
of the protein, i.e., whether it is a soluble substrate within the ER or is
a membrane protein that exposes domains in both the ER lumen and
in the cytoplasm (Fig. 1, A–B), cytoplasmic and/or ER lumenal Hsp70s
and Hsp40s may be involved in substrate recognition. The central
Hsp70 of the ER lumen, BiP, demonstrates the dual role of this class of
chaperones. BiP is involved in the maturation and folding of proteins
as well as in sensing chronically misfolded protein and targeting them
for degradation [26]. Similarly, proper formation of disulﬁde bonds is
integral to the correct folding of many secreted proteins and as such
PDIs can be an important part of the quality control machinery [1,27].In addition, there is evidence that PDIs possess a chaperone function
independent from their role in disulﬁde bond isomerization to facilitate
ERAD [24,28].
Another form of substrate recognition occurs based on the state of
the appended glycan chain on proteins within the ER [29,30]. Most
proteins that enter the secretory pathway (and that possess the
Asn-X-Ser/Thr consensus sequence) are modiﬁed by the addition of
a core oligosaccharide. The addition of sugar residues conveys infor-
mation about the folding state of the protein to the ER quality control
machinery [31,32]. In the ER, three terminal glucose residues are then
sequentially removed from the added oligosaccharide. If the protein
fails to fold, an oligosaccharide transferase, UDP–glucose glycoprotein
glucosyltransferase (UGGT), adds a glucose residue back onto the sub-
strate by virtue of the fact that this enzyme also exhibits chaperone-
like properties. Glucose re-addition by UGGT favors substrate binding
to the lectin-like chaperones calnexin and calreticulin, which along
with associated partners favor protein refolding [33,34]. But if refolding
fails to occur within a reasonable time frame, the substrate interacts
with another lectin-like chaperone, the ER degradation enhancing
α-mannosidase-like protein, EDEM1 [35]. EDEM1 functions with an
ER Hsp40 homolog that also possesses disulﬁde reductase activity to
target select, soluble ERAD substrates for retrotranslocation [36].
After the decision to degrade a protein has been made the protein
must be transported out of the ER and into the cytoplasm (if it is
soluble; Fig. 1A), or extracted from the ER membrane (if it is an inte-
gral membrane protein; Fig. 1B). This event has been referred to
as retrotranslocation or dislocation. The retrotranslocation channel
through which proteins move from the ER and into the cytoplasm is a
focus of intense investigation, but there is still no clear consensus on
which or even if a single protein constitutes this channel. Nevertheless,
one retrotranslocation channel candidate is Sec61 [37], which is also
used for protein translocation into the ER (Fig. 1C). Another candidate
is the Hrd1 complex, which consists of several associated proteins in
the ERmembrane [38,39] (Fig. 1D). Hrd1 can be crosslinked to a soluble
polypeptide as it is extracted from the ER, and also exhibits ubiquitin li-
gase activity [40], which is essential for the proteasome-mediated deg-
radation of most ERAD substrates (also see below).What is clear is that
the retrotranslocation of nearly all ERAD substrates requires the activity
of the Cdc48/p97 complex [41–43]. Cdc48 is a hexameric AAA ATPase
protein that together with its associated cofactors [44] is anchored to
the ER membrane and interacts with ubiquitinated substrates. Sequen-
tial rounds of ATP binding and hydrolysis are then used to remove both
soluble and lumenal proteins from the ER. Cdc48 associateswith a series
of cofactors that subsequently facilitate the transfer of ubiquitinated
substrates to the proteasome [45], and also associates with the
proteasome itself [46].
As noted above, protein ubiquitination is almost always required
for proteasome degradation, and not surprisingly a key event during
the delivery of an ERAD substrate for degradation is ubiquitination
[47,48]. Protein ubiquitination employs a series of enzymes; an E1
ubiquitin activating enzyme, E2 ubiquitin conjugating enzymes, and
E3 ubiquitin ligases [49]. E3 ligases catalyze the covalent attachment
of ubiquitin onto the substrate protein, either transferring ubiquitin
directly itself or by bringing the substrate to an E2 conjugating
enzyme. The E3 ubiquitin ligases are an abundant class of proteins
and are thought to provide diversity in substrate recognition, and over
the years a subgroup of cellular E3s has been shown to play an impor-
tant role during ERAD.
Together, ER protein folding and quality control are essential
processes that maintain cellular homeostasis. Not surprisingly the
ERAD pathway has been linked to a growing number of human dis-
eases [50]. While the speciﬁcs and dynamics of substrate recognition
and degradation for many proteins are still being established at the
molecular level, the basic machinery required for ERAD is now rela-
tively well-deﬁned, especially in yeast [19,51,52]. This is a notable
achievement, given that only ~20 years ago the existence of the
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Fig. 1. A. Soluble ERAD substrates must retrotranslocate across the ER bilayer in order to access the cytoplasmic proteasome (PS). B. Integral membrane proteins present domains
that can directly access the proteasome, but membrane spanning segments must still be threaded from the lipid bilayer, regardless of whether degradation occurs at the membrane
or in solution. C. The Sec61 translocation channel might be used for both protein translocation (left) and retrotranslocation (right). D. The components of the Hrd1 complex in yeast
include Der1, Usa1 (which scaffolds and regulates Hrd1 oligomerization and function) and Hrd3, which serves as a dock for lectins and chaperones. The mammalian homolog of
Hrd3 is SEL1, and Usa1 and Herp may function analogously. The Hrd1 complex also associates with Cdc48 (not shown), which extracts ERAD substrates. Also not shown is
Ubx2, which associates with the Hrd1 complex and helps anchor Cdc48 to the ER. In parts A–C, ERAD substrates are shown in purple. See text for additional details and
[39,40,180–182].
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that ERAD existed, and in the following sections we trace the scientiﬁc
developments that ultimately led to our current view of the ERAD
pathway.
3. The early history of the ERAD pathway
Throughout most of the 1980s it was assumed that damaged or
unneeded secretory proteins were disposed of exclusively by the
lysosomal pathway. The lysosome also serves as a site for large-scale
disposal of organelles and recycling of macromolecules in the process
known as autophagy [53]. Lysosomes form from Golgi-derived vesicles
and resident lysosomal proteases trafﬁc through the secretory pathway
and are ultimately delivered to the lysosome [54,55]. It was thought
that the disposal of secretory proteins proceeded by a similar route,
and indeed the lysosome is the site of degradation for proteins that
fail Golgi or plasma membrane quality control check-points [56].
Many cytoplasmic proteases also exist in the cell [57], and the
most prominent one is the proteasome. The 26S proteasome is a
large (~2.5 MDa) multicatalytic protease that is primarily cytoplas-
mic, although a signiﬁcant proteasome population exists in the nucle-
us and—intriguingly—is associated with the ER membrane [58,59].
Indiscriminant proteolysis is prevented by the preferential selection
of polyubiquitinated substrates. The proteasome cap, or the 19S par-
ticle (also known as PA700) harbors ubiquitin receptors,
deubiquitinating enzymes, and a series of AAA ATPases that unfold
and deliver substrates into the 20S proteasome core [60]. In turn,
the 20S core is a barrel-shaped chamber with two-fold symmetry
that houses duplicate copies of 3 enzymes with unique proteolytic
activities. Because the proteasome and cytoplasmic proteases were
only considered to target cytoplasmic substrates, there was no reason
to believe that these components would contribute to events underly-
ing ER quality control, especially given the lysosome's central position
as a component of the secretory pathway.
3.1. T cell antigen receptor
The ﬁrst hint that a quality control mechanism was located in the
early secretory pathway came from studies on the maturation of the T
cell antigen receptor (TCR). TCR is located on the plasma membrane
of T lymphocytes and is responsible for the recognition of antigens
presented by the major histocompatibility complex (MHC). TCR is aheteromeric complex composed of several polypeptide chains [61].
The alpha and beta chains form a disulﬁde linked heterodimer that
acts as the antigen binding region. Three additional peptide chains
(delta, gamma and epsilon) and a homodimer of two zeta chains
come together to form the functional receptor complex. Maintenance
of TCR at the surface of T cells is critical for immune system function.
Like all plasma membrane proteins, TCR subunits are directed to
the ER co-translationally and are inserted into the ER membrane.
Only completely assembled complexes reach the cell surface [62]
while partially assembled complexes are destroyed [63]. These obser-
vations hinted that the secretory pathway contains a protein quality
control check-point that selectively recognizes and mediates the
destruction of non-functional TCR complexes before they trafﬁc to
later steps of the secretory pathway.
In an important early study, the mechanism of how the cell de-
grades unassembled TCR subunits was investigated. Speciﬁcally, the
fate of individual chains of the TCR complex was followed in both T
cell hybridoma lines and ﬁbroblasts [64]. The authors discovered
that two distinct pathways ensured that only the properly formed
complex reached the plasma membrane. In T cells, individual alpha
chains were processed through the Golgi and subsequently degraded
via the lysosome. However, when expressed in ﬁbroblasts both the
alpha chains and alpha–beta complexes were degraded. Degradation
was unaffected by inhibitors of lysosomal proteolysis, indicating a sep-
arate disposal route in ﬁbroblasts. The existence of this second pathway
was conﬁrmed when treatment of T cells with compounds that blocked
ER to Golgi transport now resulted in the degradation of alpha, beta and
delta chains through a lysosome-independent mechanism. These stud-
ies were consistent with other reports hinting that the degradation of
delta chain took place early in the secretory pathway [65] via a
process then referred to as pre-Golgi or ER degradation. Nevertheless,
direct evidence that degradation occurred exclusively in the ER or
associated with the ER was lacking [66,67].
Because vesicular trafﬁc is difﬁcult to control and measure in intact
cells, permeabilized cell systems were next employed. Permeabilized
cells still support the folding and assembly of proteins and can even
carry out the redox dependent degradation of a secreted protein [68].
This system also allowed for the add-back of regulatory molecules
and speciﬁc proteins. Importantly, permeabilization destroys vesicular
trafﬁc, so that ER-speciﬁc events can be monitored.
To deﬁnitively establish that ER export was dispensable for the deg-
radation of unassembledmembers of the TCR, a chimeric tac-TCR alpha
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ﬂuorescence microscopy [69]. After treatment with cycloheximide to
inhibit new protein synthesis, the ﬂuorescent signal was rapidly lost
without any appearance outside of the ER. After the plasma membrane
was permeabilized with a pore forming toxin, SLO, a treatment previ-
ously shown to abolish export from the ER [70], Tac-TCR alpha subunit
degradation was unaffected. These data were recapitulated with a sec-
ond chimeric substrate, Tac-TCR beta. Therefore, vesicular transport
from the ER was dispensable for the degradation of the unassembled
TCR subunits.
In addition to TCR, many other cell surface receptors are multi-
subunit complexes and the assembly of these complexes occurs in
the ER [71]. Other early evidence indicated that the ER could expand
if unfolded proteins accumulated, and that misfolded proteins associ-
ated with an Hsp70 in the ER, BiP [72–78]. Thus, the ER was now im-
plicated as a potential site of general secretory protein quality control,
and a factor that might mediate this event had been identiﬁed. These
collective data provided some of the ﬁrst and best previews of the
ERAD pathway.
3.2. Human asialoglycoprotein receptor
Studies on another plasma membrane protein provided strong
supporting evidence of ER quality control and explored how substrate
degradation might proceed. The human asialoglycoprotein receptor
(AGPR) is found in liver cells and binds and removes speciﬁc glyco-
proteins from circulation. AGPR activity is closely tied to hepatic
function and decreased AGPR is a characteristic marker of a variety
of liver disorders [79]. AGPR forms a hetero-oligomer and both sub-
units are glycosylated integral membrane proteins. The functional
receptor is thought to be a trimer of two H1 and one H2 subunits
[80,81]. Similar to TCR, when expressed together the subunits were
transported to cell surface but when expressed individually they
were rapidly degraded [82,83]. Degradation was insensitive to lyso-
somal protease inhibitors, and based on the glycosylated state of the
orphaned AGPR subunits it appeared that they never reached the
Golgi. Moreover, the subunits were cleaved. Proteolysis occurred in
the ER and could be reconstituted in vitro. Interestingly, a 35 kDa
cleaved fragment was stable but it was proteolyzed further in viable
cells. The results from subsequent studies indicated that cleavage
occurred in the ER and that complete degradation was robust in the
absence of vesicular transport from the ER to the Golgi [84]. Thus,
the fragment was degraded either in the ER or in an ER associated
manner. Based on our current knowledge, one may speculate that
the proteasome or another protease might have clipped the substrate,
but that ongoing proteasomal degradation required high levels of
ATP and/or proteasome integrity, which may have been deﬁcient
in vitro.
3.3. Ribophorin I
Concurrent with studies on TCR and AGPR, another integral
membrane protein, the transmembrane glycoprotein Ribophorin I,
was examined as a substrate for ER quality control. Unlike these
other substrates, Ribophorin I is an ER resident protein that exhibits
ribosome binding properties and facilitates delivery of substrates
to the glycosylation machinery in the ER [85,86]. The Kreibich lab
discovered that C-terminally truncated versions of Ribophorin I
were unstable, in contrast to the full-length protein, and degradation
occurred in a non-lysosomal manner [87]. Interestingly, the two
truncated Ribophorins examined in this study differed: One had a
membrane anchor while the other was a soluble ER lumenal protein
that lacked the membrane anchor. It appeared that the lumenal form
of the protein had entered a pre-Golgi compartment and underwent
biphasic degradation. The authors suggested that degradation com-
menced in the ER but continued in this second compartment. Consistentwith this model, treatment with the ionophores monensin and CCCP,
which inhibit vesicular transport out of the ER [88–90], blocked the
second degradation phase if performed at the beginning but not later
after transport had occurred. These results suggested that transport be-
tween the compartments was required for the second degradation
phase.
Another observation from this study was a demonstrated require-
ment for high calcium concentrations to support degradation. This
result suggested that the calcium-rich environment within the ER is
important for quality control. We now appreciate that important
mediators of ERAD, such as BiP, calnexin, and calreticulin are calcium
binding proteins. Depletion of calcium also induces the unfolded pro-
tein response [91,92], which alters the expression of ER chaperones
and other components and might lead to complex effects on protein
degradation.3.4. MHC I and human cytomegalovirus
An important source of insight into the ERAD pathwaywas obtained
from a series of studies of another membrane receptor, this time the
major histocompatibility complex class I protein (MHC I). MHC I is
foundon the surface of all nucleated cells and is an important part of im-
mune system function. MHC I binds to short peptide sequences gener-
ated inside the cell via the proteasome and presents them at the cell
surface. These peptide antigens can be derived from breakdown of
endogenous proteins, or in the case of an infected cell, from foreign pro-
teins expressed by an invading organism [93,94]. MHC I antigen com-
plexes are monitored by cytotoxic T cells of the host organism and
recognition of foreign peptides triggers an immune response to elimi-
nate the infected cell [95].
Over the course of evolution a number of viruses have developed
ways to evade detection. The MHC I complex is one target as a virus
attempts to dampen the immune response [96]. One virus known to
target MHC I is the human cytomegalovirus (HCMV). Previous studies
had shown that cells infected with HCMV had downregulated levels of
MHC I protein [97]. A follow up study demonstrated that the US11
viral gene product could similarly downregulate MHC I when
transfected into human cells [98]. In a seminal study an investigation
into US11 revealed the mechanism by which it targeted MHC I [99].
Speciﬁcally, in the presence of US11, the heavy chain of theMHC I com-
plex was rapidly degraded while in control cells the heavy chain was
stable. The MHC I heavy chains failed to reach the Golgi and appeared
to be degraded before leaving the ER, as chemically blocking ER to
Golgi export did not stabilize the heavy chains. In contrast, the MHC I
light chains were stable and in fact were secreted from the cell in in-
creased amounts without its heavy chain partner, indicating that US11
speciﬁcally acted on the fate of the heavy chain. Even more surprising
was that upon addition of proteasome inhibitors degradation interme-
diates became detectable, indicating the possibility that heavy chain
breakdown occurred in the cytoplasm, even though US11 resided with-
in the ER. Moreover, glycans were removed from heavy chain interme-
diates in US11 transfected cells, demonstrating that US11 triggered
MHC I heavy chain deglycosylation and dislocation out of the ER. Frac-
tionation of cellular components conﬁrmed this observation as US11
remained associatedwith ERmicrosomes, and heavy chain degradation
intermediateswere found in cytosolic fractions only inUS11 transfected
cells. Thus, US11 had downregulated surface expression of MHC I by
turning the heavy chains into ERAD substrates. The authors of this
study made the very insightful commentary that the pathway to de-
stroy MHC I heavy chains may have been simply co-opted by the virus
and that it existed as a more general pathway to dispose of unwanted
membrane proteins. Follow up studies characterized another HCMV
gene that also targeted MHC I heavy chains [100] and we now know
that co-opting of the ER quality control machinery is a common mech-
anism as a virus attempts to evade the host cell immune response [101].
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Lipid synthesis takes place primarily in the ER. The synthesis of
one lipid class, the sterols, is also primarily ER-localized and the rate-
determining step in this anabolic pathway is catalyzed by HMG-CoA re-
ductase (HMGR) [102]. The product of HMGR ismevalonate. HMGR is an
ER integral membrane protein with 8 membrane spanning domains,
and its activity was known to be downregulated by degradation in
response to metabolic signals from sterol biosynthetic intermediates,
such as mevalonate [103,104].
HMGR degradation can take place in permeabilized cells [105],
and to investigate this process further a chimeric protein was created
with the HMGR membrane domains fused to beta-galactoside; the
resulting protein resided in the ER [106]. Pulse chase studies in
transfected cells demonstrated that the fusion protein remained
mevalonate-responsive. The cells were then permeabilized with digi-
tonin, a reagent that permeabilizes the plasma membrane by virtue
of its interaction with cholesterol but leaves the ER membrane
intact [107,108]. The enzyme in the permeabilized system remained
mevalonate responsive, indicating that degradation occurred in the
absence of vesicular trafﬁc from the ER. This result was consistent
with an earlier study showing that HMGR degradation was unaf-
fected by Brefeldin A treatment, which blocks export from the ER
[109]. While these results indicated that HMGR degradation was
ER-associated, there was an important hint that other components
might be involved in triggering degradation. For example, the
authors observed that metabolic induction of HMGR degradation
was only seen when mevalonate treatment was performed before
cell permeabilization, indicating that the degradation signal had to
be set in motion before the loss of cytosolic components. The cyto-
solic factors remain unknown but the requirement for mysterious,
soluble factors in these systems became a common theme in related,
subsequent studies. In retrospect, these factors might have been pro-
teins that support maximal substrate ubiquitination, or proteasome
associated components or chaperones that aid in efﬁcient substrate-
targeting to the proteasome.
Another observation in this study [106] was that the degradation of
HMGR seemed to be ATP-independent, which was inconsistent with
previous studies [105]. In this case the lack of an ATP requirement
could be connected to the observation that mevalonate treatment
only led to degradation if added before membrane permeabilization.
Thus, it is possible that the signal to degrade HMGR had already
been implemented, the substrate had already been ubiquitinated,
and the proteasome had already been recruited to HMGR at the ER
membrane. Moreover, as observed for Ribophorin I (see above), the
melvonate-triggered degradation of HMGR was highly dependent
on the concentration of intracellular calcium [110]. HMGR degradation
was also reported to be inhibited by a “cysteine protease inhibitor”,
ALLN (N-acetyl-leucyl-leucyl-norleucinal) [111], which also inhibits
the proteasome. Overall, these pioneering studies on HMGR indicated
that the ERAD pathway does not simply degrademisfolded or damaged
proteins, but can be employed to regulate essential cellular processes.
Ultimately, however, the ﬁrst, deﬁnitive evidence that HMGR degrada-
tion occurs via the ERAD pathway emerged from pioneering genetic
studies performed in yeast by Hampton and colleagues [112] and later
in mammalian cells by a number of investigators [113].
3.6. Cytochrome P450
The selectivity underlying ER quality control decisions became
quite evident when the fates of different isoforms of the rat liver
cytochrome P450 were examined. The ethanol inducible CYP2E1 is
degraded in hepatocyctes with a half-life of ~9 h whereas the CYP2B1
isozyme is longer lived with a half-life of ~21 h. The two proteins
were subsequently found to be destroyed by completely different
mechanisms. The longer lived 2B1 isoform was degraded by thelysosome [114,115]. However, the disappearance of the more rapidly
degraded 2E1 isoform was unaltered by treatment with a variety of ly-
sosomal protease inhibitors [116]. Moreover, the inclusion of imidazole,
a 2E1 substrate, stabilized the protein while the addition of glucagon
led to phosphorylation of 2E1 and increased degradation. In contrast,
the lysosome-targeted 2B1 protein was not subject to regulation by
imidazole or glucagon. These results indicated that the 2E1 form of the
cytochrome underwent non-lysosomal degradation that was highly reg-
ulated. The data also supported the notion that the conformational state
of the protein might confer recognition by the degradation machinery,
as substrate binding decreased and hormone-induced phosphorylation
increased its degradation.
3.7. Expression of yeast prepro-alpha factor in mammalian cells
Many secreted proteins are zymogens or pro-hormones that must
be processed. To develop a new model in which the link between
hormone processing and quality control might be examined, a yeast
mating hormone precursor, prepro-alpha factor, was expressed in
rat pituitary cells [117]. In yeast, the prepro-alpha factor signal
sequence is cleaved in the ER, generating pro-alpha factor, which is
then triply glycosylated and exported to the Golgi where the pro
domain is removed and the core oligosaccharide is elaborated. In
pituitary cells the protein entered the ER and underwent initial pro-
cessing and core glycosylation, as in yeast. However, glycosylated
pro-alpha factor was rapidly degraded and no mature product was
detected. The authors found that chemical inhibition of ERmannosidases
led to almost complete stabilization of the core glycosylated pro-alpha
factor whereas inhibition of ER glucosidases accelerated the already
rapid degradation of this protein; the use of these chemical reagents—
which proved essential for this study—was pioneered by the Helenius
laboratory, who had concurrently been examining how viral proteins
are subject to ER quality control [118,119]. Based on these results, the au-
thors speculated that glycosylated pro-alpha factorwas subject to quality
control because glycan processing differs between yeast and man. In-
stead, the data are more consistent with the current view of how ERAD
substrates are selected: As described above, inhibition of the glucosi-
dases prevents interaction with calnexin and calreticulin, which only
bindmono-glucosylated substrates and facilitate folding,whereas inhibi-
tion of mannosidase activity blocks delivery via EDEM1 for retro-
translocation. This study provided evidence that post-translational
modiﬁcations may serve as a signal to regulate protein degradation in
the early secretory pathway.
3.8. Peptide substrates
For many years, protein transport across the ER membrane was
thought to be a one-way street; i.e., proteins were translocated into
the ER but could only leave once they were packaged into vesicle
carriers. The ﬁrst hint that proteins—or formally, a peptide—could
retrotranslocatewas provided by examining the fate of a synthetic pep-
tide containing a three residue amino acid sequence (an Asn-Tyr-Thr
tripeptide) that acts as an acceptor site for N-linked glycosylation. This
tripeptide had been used as a tool to monitor transport through the se-
cretory pathway in mammalian cells [120], and at about the same time
an in vitro system had been established to reconstitute ER to Golgi pro-
tein transport using yeast components [121].When the transport of the
peptide and pro-alpha factor in a modiﬁed version of this in vitro sys-
tem was examined, an important discovery was made: The protein
and tri-peptide both exited the ER, but they did so by different mecha-
nisms [122]. Based on sedimentation analysis pro-alpha factor was
membrane associated whereas the peptide was freed from the mem-
brane pool. Also, antibodies that compromise ER vesicle release also
blocked pro-alpha factor release, but did not prevent peptide export.
In addition, the peptide possessed core oligosaccharides conjugated in
the ER but lacked Golgi-speciﬁc modiﬁcations. Finally, peptide export
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ognized that the peptide might be employed as a tool to characterize
this novelmechanismof peptide export from the ER, and in fact had ser-
endipitously identiﬁed one of the key steps during ERAD, the
retrotranslocation of substrates from the ER. Subsequent studies
would establish that this process is mediated by proteinaceous factors
on the cytoplasmic face of the ER [123], and that the peptide exporting
activity is conserved [124].
3.9. Alpha-1 antitrypsin
One of the ﬁrst hints that ER protein degradation might be directly
connected to the pathology underlying a human disease was obtained
from studies on alpha-1 antitrypsin (AAT). AAT is a protein produced
and secreted by hepatocytes and is the second most abundant serum
protein. In the serum AAT acts an inhibitor of neutrophil elastase
[125]. AAT also provides a vital function in the lung, where it keeps
the levels of elastase in check. In fact, AAT deﬁciency leads to a chronic
breakdown of lung tissue and emphysema.
A common disease-causing AAT mutation is known as the Z variant.
The AAT-Z mutant protein is inefﬁciently secreted and can accumulate
in the ER [126–128]. The misfolded, ER-retained AAT-Z species can
form insoluble aggregates, which in some cases results in liver disease,
but it was also noted that a signiﬁcant portion of the protein was de-
graded in a pre-Golgi compartment [129,130]. Therefore, individuals
who exclusively express AAT-Z have compromised lung function. In
later years, AAT-Z was analyzed as one of the ﬁrst soluble ER proteins
retrotranslocated and degraded by the proteasome, an event that
could be recapitulated in both a yeast AAT-Z expression system and in
transfected mammalian cells [16,131]. Since then, AAT-Z and another
mutant formof AAT, known as null HongKong (NHK), have been heavi-
ly utilized as model ERAD substrates, and much of what is now under-
stood about the quality control of glycosylated proteins in the ER has
been derived from the use of the NHK variant. It should also be noted
that AAT-Z is a substrate that can be disposed of by multiple degrada-
tion pathways [132]. While AAT-Z was one of the model substrates to
ﬁrst demonstrate the existence of ERAD, it has also clearly been
shown that AAT-Z enters the autophagy pathway and is degraded in
the lysosome [133,134]. The pathway chosen—ERAD versus autopha-
gy—seems to be related to the extent of misfolding, with more soluble
forms being disposed of by ERAD and more aggregated and insoluble
AAT-Z being routed for autophagy [135].
3.10. Immunoglobulin light chain
Another soluble secreted protein that can be targeted for degrada-
tion in the ER is the unassembled immunoglobulin light chain. During
normal B lymphocyte differentiation there is an asynchronous ex-
pression of heavy and light immunoglobulin subunits. Excess light
chains relative to the partner heavy chains are usually secreted
without assembly [136]. However the sequence of light chain varies
naturally to accommodate a vast immune repertoire. Some of these
sequence changes result in folding conformations that can destabilize
the light chain structure and even lead to aggregation [137,138]. A
number of malignant cell lines were isolated that had lost expression
of heavy chain but light chain expression persisted. One such cell line
is the murine lymphoma CH12kappa. In this line, the kappa light
chains are produced but fail to be secreted [139]. To determine the
mechanism underlying this phenomenon, Argon and colleagues
[140] examined the fate of kappa light chains under a variety of
conditions. First, they discovered that the failure to be processed
was an intrinsic property of the unassembled kappa light chain.
After exclusive expression of kappa in another myeloma line or in
ﬁbroblasts, the protein remained secretion-incompetent and was
degraded. Pulse chase studies showed the free kappa chains to be de-
graded with no lag time and at a signiﬁcantly greater rate than otherlight chains expressed in the same system. However, the kappa light
chains were not defective; when the corresponding heavy chain
partner was co-expressed the light chains were assembled and
functional immunoglobulin was secreted. Treatment with monensin,
m-chlorophenylhydrazone, or brefeldin A, which disrupts ER to
Golgi or inter-Golgi transport, had no effect on kappa degradation,
suggesting that transit beyond the ER was dispensable for degrada-
tion. As anticipated, then, inhibitors of endosomal and lysosomal pro-
teases had no effect on kappa degradation, and the kappa light chains
co-localized with the ER resident chaperone, BiP, as determined by
immunoﬂuorescence microscopy. Further, the light chains associated
with BiP, consistent with other studies that had implicated BiP as a
component of light chain quality control [141,142]. The light chains
also associated with GRP94 after chemical crosslinking and immuno-
precipitation [140]. GRP94 is another abundant ER resident chaper-
one, and recently this Hsp90 homolog was found to reside in a
complex with a network of other factors that plays a role in ERAD
substrate selection [143].
3.11. ER-60, the long-sought ER protease?
Based on the studies discussed in the preceding sections, there
was clearly signiﬁcant interest in identifying an ER resident, quality
control protease. At this time, the concept of the proteasome or an-
other cytosolic protease degrading ER membrane proteins—let alone
ER lumenal proteins—was not entertained. Several of the papers
described above had implicated serine and/or cysteine proteases,
suggesting the involvement of at least one ER protease. To identify
these proteases, the quality control of misfolded, mutant versions of
human lysozymewere examined. Unlike wild type lysozyme, the mu-
tant forms are retained in the ER and degraded [144]. Degradation of
mutant lysozyme was then shown to be sensitive to cysteine protease
inhibitors and chemical crosslinking identiﬁed a protein known as
ER-60 as well as protein disulﬁde isomerase (PDI) as lysozyme part-
ners [145]. ER-60 had previously been isolated from rat liver and
appeared to exhibit cysteine protease activity [146]. In vitro assays
suggested that ER-60 could degrade chemically denatured mutant
lysozyme but not the wild type substrate. Based on these promising
results and the fact that PDI aids in the maturation of disulﬁde-
bonded secreted proteins [1], it was thought that ER-60 was the
long sought ER quality control protease. However, evidence for a
broader role of ER60 in the degradation of other substrates never
materialized, and it is likely that initial reports contained an unknown
contaminating protease activity. In the end ER-60 was re-annotated
as p57, which is a calnexin associated disulﬁde isomerase in the PDI
family [147].
3.12. Degradation of a Sec61 mutant and a connection to the
ubiquitin pathway
Each of the studies described in the previous sections employed
biochemical techniques and utilized mammalian cells. A signiﬁcant
breakthrough in our understanding of the machinery that mediates
ER protein degradation came about from a genetic study in yeast
[148]. In this study, the fate of a mutant version of the Sec61 translo-
cation channel was examined. The mutation in the SEC61 gene results
in a destabilized protein at 37 °C, and as a result the sec61 yeast strain
is inviable at this temperature. Thus, extragenic suppressors of the
growth phenotype could be identiﬁed, which in turn might be re-
sponsible for the degradation of Sec61. One identiﬁed suppressor
was Ubc6, which is a ubiquitin conjugating enzyme (E2) that associ-
ates with the ER membrane and whose active site faces the cyto-
plasm. The loss of Ubc6 also restored efﬁcient ER translocation in
the sec61 mutant, demonstrating that both the translocation
channel's levels and function had been corrected. These results sug-
gested that ER protein quality control might require cytoplasmic
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ty control. In a subsequent study, the Sommer group conﬁrmed this
supposition [149]. Conditionally mutant forms of both the Sec61 pro-
tein, as well as one of its partners, Sss1 [150], were subject to regulated
degradation at non-permissive temperatures in a ubiquitin and
proteasome-dependent manner. As anticipated, degradation took
place at the ER membrane. Based on these results it was suggested
that the ubiquitin–proteasome system might be responsible for other
examples of ER protein degradation, as observed in earlier studies.
3.13. The cystic ﬁbrosis transmembrane conductance regulator (CFTR)
Concurrent with these experiments, several laboratories began
to investigate another substrate but in this case its selection by the ER
quality controlmachinery is linked to human disease. The cystic ﬁbrosis
transmembrane conductance regulator, CFTR, had been shown to be a
highly unstable protein: Only 25% of the wild type protein matured in
the ER and could trafﬁc to the plasma membrane, thus escaping the
ER degradation machinery [6]. In turn, a disease-associated deletion of
Phe at position 508 in the protein (deltaF508-CFTR), resulted in the
complete destruction of CFTR and the absence of this polytopic mem-
brane protein at the plasma membrane in epithelial cells.
To deﬁne the pathway that leads to CFTR degradation, various
protease inhibitors, including those that had recently shown activity
against the cytoplasmic proteasome, were examined for their effects
on CFTR [151]. The peptide aldehyde ALLN slowed but did not
completely prevent the degradation of immature CFTR. However, a
more speciﬁc proteasome inhibitor, MG132, completely blocked the
degradation of immature CFTR. In no case did the prevention of
degradation lead to the appearance of mature CFTR, suggesting that
the restoration of functional protein required an earlier, corrective
step in the quality control pathway; this supposition has been
borne-out [152]. A direct link between CFTR degradation and the
ubiquitination–proteasome pathway was also established in a com-
panion study [153]. Here, the authors showed that immature CFTR
was polyubiquitinated, and that concurrent with stabilization of
CFTR by ALLN the ubiquitin signal signiﬁcantly increased. In addition,
co-expression of the K48R ubiquitin mutant, which is unable to
form polyubiquitin chains, led to a massive increase in deltaF508
CFTR, strongly suggesting that polyubiquitination was required for
CFTR degradation. Further, CFTR accumulated in a cell line that
expressed a temperature sensitive allele of the E1 ubiquitin activating
enzyme [154]. Taken together, these results provided the ﬁrst direct
evidence that misfolded ER membrane proteins access the cytoplasmic
ubiquitin–proteasome system. Though the authors did not know the
mechanism bywhich this membrane protein was selected for degrada-
tion, a large cytoplasmic domain of CFTR was known to interact with
members of the Hsp70 chaperone family [155,156]. It is now clear
that a myriad of chaperones associate with immature forms of CFTR,
particularly the delta508 variant, and select the proteins for
ubiquitin-dependent degradation by the proteasome [157].
3.14. Yeast proalpha factor and the reconstitution of ER associated
degradation
By the middle of the 1990s it was becoming apparent that a sys-
tem to identify and degrade a variety of aberrant integral membrane
proteins from the ER existed, and that the ubiquitin–proteasome
might play a role in this process. It was unknown, however, how
soluble secreted proteins within the ER were degraded since they
seemed unable to access the cytoplasmic components that constituted
the ubiquitin–proteasome system. Moreover, additional components
required for ER protein degradationmost probably existed but remained
mysterious. Signiﬁcant progress toward these ends was made with the
development of an in vitro system using components derived from
yeast [158].As described above, the yeast prepheromone prepro-alpha factor
translocates into the ER, and after the signal sequence is cleaved the
resulting protein, pro-alpha factor, is glycosylated. However, if glycosyl-
ation is prevented, the protein is degraded in yeast [159]. Therefore,
genetic and chemical tools were used to introduce an unglycosylated
version of pro-alpha factor into isolated, ER-derived vesicles from
yeast. When concentrated yeast cytosol and an ATP-regenerating sys-
tem were added, the pro-alpha factor was rapidly and quantitatively
degraded [158]. This system permitted the introduction of ER or cyto-
solic components prepared from mutant yeast strains, allowing for the
testing of essentially any factor that might facilitate pro-alpha factor
degradation. Calnexin as well as a number of other chaperones were
subsequently identiﬁed as being critical for selecting pro-alpha factor
for degradation [24,25,158,160].
What remained curious was why degradation required the addition
of cytoplasm, but based ondata emerging from the literature itwas pos-
sible that the substrate had somehow accessed the cytoplasmic space.
Indeed, by introducing a centrifugation step during the degradation
reaction, it was evident that pro-alpha factor had entered the cytoplasm
in an ATP-dependent manner [158]. To test whether the substrate was
subject to proteasomal degradation, cytosol from a proteasomemutant
was examined in this in vitro system, as well as wild type cytosol incu-
bated with a proteasome inhibitor. In both cases, pro-alpha factor deg-
radation was signiﬁcantly attenuated and the substrate accumulated in
the cytosol. These data established that defective, soluble proteins in the
ER could be selected, returned to the cytoplasm, and degraded by the
proteasome [16]. Based on the fact that ER associated components
were required for degradation, the process was called ERAD.
3.15. A mutant form of carboxypeptidase Y, CPY*
In the same year, another study in the yeast system demonstrated
that a soluble proteinwithin the ER could be selected, retrotranslocated,
and degraded by the proteasome. The protein was a mutant form of the
yeast vacuolar protease carboxypeptidase Y (CPY*) that was trapped in
the ER and degraded [161]. Based on the easewithwhich CPY* degrada-
tion could be monitored in various mutant strain backgrounds, CPY* is
now one of the most widely used ERAD substrates. In this ﬁrst report,
it was shown that CPY* degradation was dependent on an integral
membrane ubiquitin conjugating enzyme in the ER, Ubc7, and on the
26S proteasome. Subsequent work established that CPY* degradation
was BiP-dependent and might require the Sec61 translocation channel
for delivery into the cytoplasm [162]. Genetic screens to isolatemutants
that accumulated CPY* led to the isolation of an integralmembrane pro-
tein that plays a critical role during the ERAD of many substrates [163].
Because CPY* is both glycosylated and disulﬁde bonded, this substrate
has also been used to deﬁne more speciﬁcally how defects in folding
result in ERAD (see for example [164,165]).
4. Concluding remarks
In the 10 years from the mid-1980s, when the ﬁrst reports on TCR
subunit degradation appeared, to the mid-1990s, when the ubiquitin–
proteasome system was implicated in the degradation of both soluble
and integral membrane proteins in the early secretory pathway, the
ER quality control ﬁeld grew rapidly. Since then, a large and diverse
group of ERAD substrates have been identiﬁed and the requirements
for their disposal have been dissected. To date, there are almost 70
ERAD substrates linked to a variety of human diseases [50]. In the case
of cystic ﬁbrosis, an understanding of the quality control decisions in
the ER has led to the identiﬁcation of therapeutics that may be used to
help alleviate disease [166].
Among the components of the ERAD machinery that have been
identiﬁed and characterized in the intervening years are the many
subclasses of molecular chaperones which sense misfolded proteins
and cooperate with and deliver these misfolded substrates to ER
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generally thought to simply target exposed hydrophobic motifs on
unfolded proteins, it remains mysterious why so many different
chaperones are needed to efﬁciently degrade a given ERAD substrate.
It is still unclear exactly how non-glycosylated substrates are ulti-
mately selected as substrates and this is a current area of active re-
search [167]. Further, the number of proteins identiﬁed as E3 ligases
has grown tremendously and indicates the large potential diversity
in substrate recognition [48]. The E3 ligases themselves are part of
large multi-protein complexes and have become appreciated as
central players in the organization and regulation of protein quality
control [17]. What is relatively mysterious, however, is the nature of
the polyubiquitin chain that targets ERAD substrates from proteasomal
degradation [168]. Lys-48 polyubiquitin linkages are generally thought
to dictate proteasome targeting, but a mass spectrometry study also
identiﬁed K-11 linkages as residing in ERAD substrates [169]. Whether
mixed chains exist on ERAD substrates, and which E3s cooperate to
append these various chains are unknown. We have also come further
in our understanding of how glycosylation regulates the folding and
degradation of secreted proteins. It is now known that not only the
type of glycans present and the timing of addition are important, but
also the positioning of the sugar residues can have signiﬁcant effects
on the dynamics of degradation [170,171]. Nevertheless, these studies
have only been performed on a limited number of ERAD substrates.
While great progress has also beenmade in the understanding of the
ERAD requirements for speciﬁc substrates this pursuit will become vital
as new ERAD substrates are identiﬁed. In some cases substrate-speciﬁc
factors, which are required for ERAD, exist [172]. It will be exciting to
determine whether additional and as yet uncharacterized substrate-
speciﬁc ERAD effectors exist. Another major “black box” in the ﬁeld is
the nature of the retrotranslocation channel. Several viable candidates
for this channel are nowknowndue to their interactionwithmembrane
bound proteasomes or ERAD substrates targeted for proteasomal degra-
dation. Proteasomes are localized throughout the cell and while some
are free in the cytoplasm others associate with the ER membrane
[173]. Several studies have provided evidence that the proteasome
binds directly to the translocon channel Sec61 and at least for some sub-
strates the same channelmay beused for retrotranslocation from the ER
to the cytoplasm [37,162,174–176]. Other studies have suggested that
different protein channels act during retrotranslocation (e.g., Derlin
and Hrd1 [40,177,178]). Therefore, it remains possible that multiple
channels could be used for retrotranslocation or dislocation, depending
on the speciﬁc substrate and with which quality control components it
interacts.
The mechanism that leads to a soluble substrate ﬁrst accessing the
cytoplasmic space is another area that is still actively being investigated,
though progress has been made on the pathway that at least some
substrates follow from being selected for ERAD to being delivered to a
retrotranslocon [179]. Similarly, the degree to which a protein must be
unfolded before it is selected for ERAD is unclear, as sensitive cellular
read-outs for alterations in protein conformation are lacking. Finally,
efforts to manipulate protein folding dynamics and to alter ERAD sub-
strate selection in cell models and in animals are now of vital medical
signiﬁcance, and this represents a major aim in future research efforts.
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